NVOOverviewFundamentalsDividendsTechnicalsRiskCatalystsNewsFinancial DataAIQ Pro
Current stock page

Catalysts

NVO Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareDrug Manufacturers - GeneralScore data as of Sep 1, 2026

NVO

Catalysts
Novo Nordisk A/S
Healthcare· Drug Manufacturers - General
AIQ Score
NeutralAIQ Edge 9/10
Relative Leader / Watch
Strong Relative Position
Score data as of Sep 1, 2026
Last price
$45.12
-$0.21 (-0.46%)
Latest market quote
Momentum36
Value59
Quality91
Risk Resilience45
Sentiment79
View financial data

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Nov 4, 2026

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 61/100

Momentum 36/100 and sentiment 79/100 before the next covered event.

Recent coverage
3 articles

Updated Sep 2, 2026 · Sentiment 24.85%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 36/100AIQ Edge 9/10 Strong Relative Position
Beat rate
88%
7 of 8 reported periods
Average surprise
+11.2%
Across covered historical reports
Latest result
+17.1%
Aug 5, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Aug 5, 2026—$0.82$0.96+17.1%$10.89B$12.13B
May 6, 2026—$0.87$1.04+19.5%$10.86B$11.02B
Feb 3, 2026—$0.90$1.00+11.1%$12.13B$12.5B
Nov 5, 2025—$0.77$1.02+32.5%$11.94B$11.53B
Aug 6, 2025—$0.93$0.97+4.3%$11.92B$11.97B
May 7, 2025—$0.92$0.92+0.0%$11.7B$11.9B
Feb 5, 2025—$0.88$0.91+3.4%$11.55B$11.86B
Nov 6, 2024—$0.87$0.88+1.4%$10.48B$10.68B

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Hold
4
Buy
11
Hold
12-month analyst target
$47.00
+4.17% versus current price
Based on 2 analyst observations. Targets are estimates, not predictions.
Low target
$47.00
+4.17% vs latest price
Average target
$47.00
+4.17% vs latest price
High target
$47.00
+4.17% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateNov 4, 2026

Next known earnings or reporting date.

EPS estimate$0.80

Current analyst expectation for the upcoming report.

Revenue estimate$11.22B

Current analyst expectation for the upcoming report.

Sentiment score79

News pressure around the setup.

Momentum score36

Where event reaction would show up first.

AIQ score61/100

Composite decision read before event confirmation.

Analyst context

Consensus
Hold
Analysts
2
Average target
$47.00
Target upside
4.17%
Target range
$47.00 - $47.00
90-day revisions
-3

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
2
Neutral
1
Negative
0
manilatimes.net · Aug 31, 2026

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 31 August 2026 - On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the 'Safe Harbour Rules'). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

seekingalpha.com · Aug 31, 2026

Novo Nordisk: Why The Price Remains Stubbornly Low (Rating Downgrade) (NYSE:NVO)

Novo Nordisk (NVO) is under pressure after Q2 2026 results: Wegovy pill gains but sales missed.

insidermonkey.com · Aug 24, 2026

Eli Lilly (LLY) Is Suing Six Companies Over an Unapproved Drug—Leaving Novo Nordisk (NVO) Clear in the GLP-1 Wars

On August 12, 2026, Eli Lilly and Company (NYSE:LLY) said that it filed six lawsuits against US companies it accuses of illegally selling black-market versions of retatrutide.

Open full news and sentiment

Related Links

NVO Catalysts FAQ

What are the next catalysts for NVO stock?

NVO's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move NVO stock?

Upcoming events that could move NVO include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could NVO's next earnings report affect the stock?

NVO's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive NVO stock higher?

NVO could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt NVO stock?

NVO could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.